Rat Pharmacokinetics and In Vitro Metabolite Identification of KM-819, a Parkinson’s Disease Candidate, Using LC-MS/MS and LC-HRMS
Molecules · 2024
DOI: 10.3390/molecules29051004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2024. Verfasst von Hae-In Choi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School of New Drug Discovery and Development, Chungnam National University, Daejeon 34134, Republic of Korea. Hauptthemen laut MEDLINE: Tandem Mass Spectrometry, Parkinson Disease, Formates, Organic Chemicals. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
FAF1 (FAS-associated factor 1) is involved in the activation of Fas cell surface death receptors and plays a role in apoptosis and necrosis. In patients with Parkinson’s disease, FAF1 is overexpressed in dopaminergic neurons in the substantia nigra. KM-819, an FAF1 inhibitor, has shown potential for preventing dopaminergic neuronal cell death, promoting the degradation of α-synuclein and preventing its accumulation. This study aimed to develop and validate a quantitative analytical method for determining KM-819 levels in rat plasma using liquid chromatography–tandem mass spectrometry. This method was then applied to pharmacokinetic (PK) studies in rats. The metabolic stability of KM-819 was assessed in rat, dog, and human hepatocytes. In vitro metabolite identification and metabolic pathways were investigated in rat, dog, and human hepatocytes. The structural analog of KM-819, namely N-[1-(4-bromobenzyl)-3,5-dimethyl-1H-pyrazol-4-yl]-2-(phenylsulfanyl) acetamide, served as the internal standard (IS). Proteins were precipitated from plasma samples using acetonitrile. Analysis was carried out using a reverse-phase C18 column with a mobile phase consisting of 0.1% formic acid in distilled water and 0.1% formic acid in acetonitrile. The analytical method developed for KM-819 exhibited linearity within the concentration range of 0.002–10 μg/mL in rat plasma. The precision and accuracy of the intra- and inter-day measurements were
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate School of New Drug Discovery and Development, Chungnam National University, Daejeon 34134, Republic of Korea.
- College of Pharmacy, Woosuk University, Wanju 55338, Republic of Korea.
- College of Biological Sciences and Biotechnology, Chungnam National University, Daejeon 34134, Republic of Korea.
- Biopharmaceutical Division, Kainos Medicine Inc., Seongnam 13488, Republic of Korea.
ORCID-Profile: Jin Woo Kim, Yoon-Jee Chae, Tae-Sung Koo
Förderung
- National Research Foundation of Korea
Zitieren
APA
Choi, H. I., Kim, T., Kim, J. W., Lee, G. J., Choi, J., Chae, Y. J., Kim, E., & Koo, T. S. (2024). Rat Pharmacokinetics and In Vitro Metabolite Identification of KM-819, a Parkinson’s Disease Candidate, Using LC-MS/MS and LC-HRMS. Molecules. https://doi.org/10.3390/molecules29051004
Vancouver
Choi HI, Kim T, Kim JW, Lee GJ, Choi J, Chae YJ, et al. Rat Pharmacokinetics and In Vitro Metabolite Identification of KM-819, a Parkinson’s Disease Candidate, Using LC-MS/MS and LC-HRMS. Molecules. 2024. doi:10.3390/molecules29051004
BibTeX
@article{Choi2024,
author = {Choi, Hae-In and Kim, Taeheon and Kim, Jin Woo and Lee, Gi Ju and Choi, Jinyoung and Chae, Yoon-Jee and Kim, Eunhee and Koo, Tae-Sung},
title = {Rat Pharmacokinetics and In Vitro Metabolite Identification of KM-819, a Parkinson’s Disease Candidate, Using LC-MS/MS and LC-HRMS},
journal = {Molecules},
year = {2024},
doi = {10.3390/molecules29051004}
}
EUVIMED